Discover how a groundbreaking NLRP3 inhibitor is revolutionizing the treatment of gout caused by monosodium urate crystals, offering new hope for sufferers of this painful condition.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout.
Park et al., Front Immunol 2023
<!– DOI: 10.3389/fimmu.2023.1307739 //–>
https://doi.org/10.3389/fimmu.2023.1307739
The study introduces SLC3037, a novel NEK7 inhibitor designed from 2,7-substituted thieno[3,2-d]pyrimidine derivatives, as a potential therapeutic agent against diseases triggered by NLRP3 inflammasome activation, including gout. The research demonstrates that SLC3037 effectively inhibits the NLRP3 inflammasome by blocking the binding of NLRP3 to NEK7 and its oligomerization, as well as ASC oligomerization/phosphorylation. This was evidenced through various methods including ELISA, immunoblotting, immunoprecipitation, and Blue Native gel electrophoresis. Importantly, in vivo experiments showed that SLC3037 significantly reduced foot pad thickness and inflammation in MSU-injected mice, outperforming colchicine, a standard gout treatment. Additionally, SLC3037 did not cause the decrease in the number and height of intestinal villi observed with colchicine treatment. This suggests that SLC3037 not only has superior anti-inflammatory effects but also a better safety profile, highlighting its potential as a novel treatment for gout and possibly other NLRP3 inflammasome-related diseases.